Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESRRA | P11474 | 3/20 | 0.45 |
| ▸ | ESR1 | P03372 | 2/20 | 0.45 |
| ▸ | ESR2 | Q92731 | 2/20 | 0.45 |
| ▸ | P2RY12 | Q9H244 | 1/20 | 0.41 |
| ▸ | CA12 | O43570 | 3/20 | 0.35 |
| ▸ | CA9 | Q16790 | 3/20 | 0.35 |
| ▸ | BRD4 | O60885 | 2/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | PPARG | P37231 | 2/20 | 0.34 |
| ▸ | CA1 | P00915 | 2/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.33 |
| ▸ | CA2 | P00918 | 1/20 | 0.33 |
| ▸ | DHODH | Q02127 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | CNR1 | P21554 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9922787 | 0.92 | P2RY12 (0.50) | ESRRAESR1ESR2P2RY12CA12 | |
| SCHEMBL9922785 | 0.89 | ESRRA (0.42) | ESRRAESR1ESR2P2RY12CA12 | |
| SCHEMBL13182775 | 0.88 | P2RY12 (0.40) | ESRRAESR1ESR2P2RY12CA12 | |
| SCHEMBL12177271 | 0.88 | P2RY12 (0.35) | ESRRAESR1ESR2P2RY12CA12 | |
| SCHEMBL12177298 | 0.88 | P2RY12 (0.39) | ESRRAESR1ESR2P2RY12CA12 | |
| SCHEMBL12161546 | 0.88 | ESRRA (0.43) | ESRRAESR1ESR2P2RY12CA12 | |
| SCHEMBL13638621 | 0.84 | P2RY12 (0.42) | P2RY12CA12CA9BRD4PPARG | |
| SCHEMBL9923020 | 0.84 | P2RY12 (0.41) | ESRRAP2RY12CA12CA9BRD4 | |
| SCHEMBL9922788 | 0.84 | P2RY12 (0.49) | ESRRAESR1ESR2P2RY12LMNA | |
| SCHEMBL12177188 | 0.82 | P2RY12 (0.40) | P2RY12CA12CA9BRD4PPARG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120149688-A1 | PLATELET ADP RECEPTOR INHIBITORS | PORTOLA PHARMACEUTICALS, INC. (US) | 2012-06-14 | — | — | US | disclosed |
| US-20080194597-A1 | Asulfonyl(urea, thiourea, guanidine, cyanoguanidine) compounds; cardiovascular disorders; thrombosis | PORTOLA PHARMACEUTICALS, INC. (US) | 2008-08-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080194597-A1 | Asulfonyl(urea, thiourea, guanidine, cyanoguanidine) compounds; cardiovascular disorders; thrombosis | PIGS, GP6, ASGR1 | ESRRA 3854/4885ESR1 3622/4885ESR2 3137/4885 |
| US-20120149688-A1 | PLATELET ADP RECEPTOR INHIBITORS | TBXA2R, GP6, P2RY6 | ESRRA 2670/4885ESR1 2215/4885ESR2 1817/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.